Inhibrx Q4 2023 GAAP EPS $(1.73) Misses $(1.04) Estimate, Sales $1.63M Beat $50.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Inhibrx (NASDAQ:INBX) reported Q4 2023 GAAP EPS of $(1.73), missing the $(1.04) estimate, but sales of $1.63M exceeded the $50.00K estimate, marking a 496.35% increase from the previous year.

February 28, 2024 | 2:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Inhibrx reported a significant miss on EPS but exceeded sales estimates by a wide margin in Q4 2023.
The significant miss on EPS could concern investors about profitability, potentially putting downward pressure on the stock. However, the substantial beat on sales estimates and the impressive year-over-year sales growth could signal strong demand for Inhibrx's products, potentially offsetting concerns about profitability in the short term. The mixed results make the short-term impact on the stock price uncertain, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100